■长期不受控制的高血糖已被证明会引起氧化应激,炎症,糖尿病患者的血栓形成和血管生成上调,这些都有助于糖尿病视网膜病变的发展和进展。发现维生素E具有抗炎作用,抗氧化,抗血栓形成和抗血管生成可能在糖尿病视网膜病变的早期治疗中发挥重要作用。这项研究旨在研究富含生育三烯酚的维生素E(Tocovid)对糖尿病性视网膜病变患者视网膜微出血和糖尿病性黄斑水肿进展的影响。
■这是一个多中心,随机化,双盲,安慰剂对照试验,纳入55名符合条件的参与者。治疗组(n=22)的参与者每天两次接受Tocovid200mg,而安慰剂组(n=23)的参与者每天两次接受安慰剂。两组将在治疗的总持续时间为12个月。两种视网膜体征都将在基线时进行评估,2个月,治疗6个月和12个月以确定糖尿病性视网膜病变的进展。还在与视网膜发现相似的时间点分析了反映眼中血管生成过程的血清血管内皮生长因子。
■治疗12个月后,安慰剂组视网膜微出血显著增加23.42%(p<0.05),但Tocovid组无明显变化.此外,在12个月期间,Tocovid组糖尿病性黄斑水肿面积显着减少48.38%(p<0.05),但安慰剂组无明显变化。同时,两组血清血管内皮生长因子水平比较无显著差异。
■这些发现可能表明Tocovid在预防早期糖尿病视网膜病变进展方面具有重要作用。
UNASSIGNED: Prolonged uncontrolled hyperglycaemia has shown to cause oxidative stress, inflammation, thrombosis and upregulation of angiogenesis in diabetics, which all contributes to diabetic retinopathy development and progression. Vitamin E is found to have anti-inflammatory, anti-oxidative, anti-thrombogenic and anti-angiogenesis which could play an important role in early treatment of diabetic retinopathy. This study aims to investigate the effect of Tocotrienol-rich vitamin E (Tocovid) on the progression of retinal microhaemorrhages and diabetic macular oedema in patients with diabetic retinopathy.
UNASSIGNED: This is a multi-centred, randomized, double-blinded, placebo-controlled trial which involved 55 eligible participants. The participants in the treatment group (n = 22) received Tocovid 200 mg twice daily while those in the placebo group (n = 23) would receive placebo twice daily. Both groups will be on the treatment for a total duration of 12 months. Both retinal signs will be assessed at baseline, 2 months, 6 months and 12 months of treatment to determine the progression of diabetic retinopathy. Serum vascular endothelial growth factor which reflects on the angiogenesis process in the eye was analysed as well at similar time points as the retinal findings.
UNASSIGNED: After 12 months of treatment, the placebo group had a significant increase of 23.42% in retinal microhaemorrhages (p < 0.05), but the Tocovid group had no significant changes. Moreover, the Tocovid group showed a significant decrease of 48.38% in area of diabetic macular oedema over the 12 months period (p < 0.05), but the placebo group had no significant changes. Meanwhile, there was no significant difference in serum vascular endothelial growth factor level when comparing between both groups.
UNASSIGNED: These findings could indicate that Tocovid has an important role in preventing early diabetic retinopathy progression.